The Lancet Gastroenterology & Hepatology

Published by: Elsevier Inc.  

People

  1. Abou-Alfa
    Abou-Alfa
  2. Ilson
    Ilson
  3. El Dika
    El Dika
  4. Stadler
    Stadler

Groups

  1. Department of Medicine (6)
  2. Solid Tumor Oncology Division (6)
  3. Gastrointestinal Oncology Service (5)
  4. Center for Pancreatic Cancer Research (1)
  5. Clinical Genetics Service (1)
  6. Population Sciences Research Program (1)
Search Within
  1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (3)
  2. Editorial (2)
  3. Correspondence (1)
Groups
  1. Department of Medicine (6)
  2. Solid Tumor Oncology Division (6)
  3. Gastrointestinal Oncology Service (5)
  4. Center for Pancreatic Cancer Research (1)
  5. Clinical Genetics Service (1)
  6. Population Sciences Research Program (1)
People
  1. David Ilson (2)
  2. Ghassan Abou-Alfa (2)
  3. Imane El Dika (1)
  4. Maeve Lowery (1)
  5. Zsofia Stadler (1)
Years
  1. 2023 (1)
  2. 2022 (1)
  3. 2021 (1)
  4. 2019 (2)
  5. 2017 (1)
Publishers
  1. Elsevier Inc. (6)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Less is more: Rethinking colorectal cancer resection strategies in Lynch syndrome
    Editorial

    Katona, B. W.; Stadler, Z. K.
    The Lancet Gastroenterology & Hepatology (2023)

    Fulltext@MSK | Save
  • Emerging evidence for VEGF and immune checkpoint inhibition in oesophagogastric cancer
    Correspondence

    Ilson, D. H.
    The Lancet Gastroenterology & Hepatology (2022)

    Fulltext@MSK | Save
  • Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: Mature results from a multicentre, open-label, single-arm, phase 2 study
    Journal Article

    Javle, M.; Roychowdhury, S.; Kelley, R. K.; Sadeghi, S.; Macarulla, T.; Weiss, K. H.; Waldschmidt, D. T.; Goyal, L.; Borbath, I.; El-Khoueiry, A.; more...
    The Lancet Gastroenterology & Hepatology (2021)

    Fulltext@MSK | Save
  • Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: A phase 1 study
    Journal Article

    Lowery, M. A.; Burris, H. A. 3rd; Janku, F.; Shroff, R. T.; Cleary, J. M.; Azad, N. S.; Goyal, L.; Maher, E. A.; Gore, L.; Hollebecque, A.; more...
    The Lancet Gastroenterology & Hepatology (2019)

    Fulltext@MSK | Save
  • Stage II gastric cancer: 1 year of S-1 remains standard of care
    Editorial

    Ilson, D. H.
    The Lancet Gastroenterology & Hepatology (2019)

    Fulltext@MSK | Save
  • The role (if any) of chemotherapy in hepatocellular carcinoma
    Journal Article

    El Dika, I.; Abou-Alfa, G. K.
    The Lancet Gastroenterology & Hepatology (2017)

    Fulltext@MSK | Save

    • The Lancet Gastroenterology & Hepatology – authorized name for:

    Name ISSN / ISBN Publisher
    Lancet Gastroenterology & Hepatology 2468-1253 Elsevier Inc.
    The Lancet Gastroenterology & Hepatology 2468-1253 Elsevier Inc.
    The Lancet Gastroenterology & Hepatology 2468-1253 Elsevier Inc.
    The Lancet Gastroenterology & Hepatology 2468-1253 Elsevier Inc.
    The Lancet Gastroenterology & Hepatology 2468-1253 Elsevier Inc.
    The Lancet Gastroenterology and Hepatology 24681253 Elsevier Inc.
    The Lancet Gastroenterology and Hepatology 24681253 Elsevier Inc.
    The Lancet Gastroenterology and Hepatology 24681253 Unknown
    The Lancet. Gastroenterology & Hepatology 2468-1253 Elsevier Inc.